These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II). Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924 [TBL] [Abstract][Full Text] [Related]
7. A Real-World Experience With the Supera Interwoven Nitinol Stent in Femoropopliteal Arteries: Midterm Patency Results and Failure Analysis. Myint M; Schouten O; Bourke V; Thomas SD; Lennox AF; Varcoe RL J Endovasc Ther; 2016 Jun; 23(3):433-41. PubMed ID: 27004494 [TBL] [Abstract][Full Text] [Related]
8. Analysis of endovascular therapy for femoropopliteal disease with the Supera stent. Montero-Baker M; Ziomek GJ; Leon L; Gonzales A; Dieter RS; Gadd CL; Pacanowski JP J Vasc Surg; 2016 Oct; 64(4):1002-8. PubMed ID: 27444365 [TBL] [Abstract][Full Text] [Related]
9. Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. Scheinert D; Werner M; Scheinert S; Paetzold A; Banning-Eichenseer U; Piorkowski M; Ulrich M; Bausback Y; Bräunlich S; Schmidt A JACC Cardiovasc Interv; 2013 Jan; 6(1):65-71. PubMed ID: 23347863 [TBL] [Abstract][Full Text] [Related]
10. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year. Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions. Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575 [TBL] [Abstract][Full Text] [Related]
12. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476 [TBL] [Abstract][Full Text] [Related]
13. A midterm analysis of patients who received femoropopliteal helical interwoven nitinol stents. Chan YC; Cheng SW; Cheung GC J Vasc Surg; 2020 Jun; 71(6):2048-2055. PubMed ID: 32081479 [TBL] [Abstract][Full Text] [Related]
14. Midterm Patency After Femoropopliteal Interventions: A Comparison of Standard and Interwoven Nitinol Stents and Drug-Coated Balloons in a Single-Center, Propensity Score-Matched Analysis. Steiner S; Schmidt A; Bausback Y; Piorkowski M; Werner M; Yahiaoui-Doktor M; Banning-Eichenseer U; Scheinert D J Endovasc Ther; 2016 Apr; 23(2):347-55. PubMed ID: 26848131 [TBL] [Abstract][Full Text] [Related]
15. Endovascular first strategy for de novo TransAtlantic Inter-Society Consensus C and D femoro-popliteal disease: mid-term outcomes from a single tertiary referral center. Grenville JL; Tan KT; Moshonov H; Rajan DK Vascular; 2015 Feb; 23(1):31-40. PubMed ID: 24695358 [TBL] [Abstract][Full Text] [Related]
16. Comparison of drug-eluting balloon angioplasty with self-expanding interwoven nitinol stent deployment in patients with complex femoropopliteal lesions. Teymen B; Akturk S; Akturk U; Tdjani M Vascular; 2018 Feb; 26(1):54-61. PubMed ID: 28708023 [TBL] [Abstract][Full Text] [Related]
17. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. McQuade K; Gable D; Pearl G; Theune B; Black S J Vasc Surg; 2010 Sep; 52(3):584-90; discussion 590-1, 591.e1-591.e7. PubMed ID: 20598480 [TBL] [Abstract][Full Text] [Related]
18. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. Zeller T; Peeters P; Bosiers M; Lammer J; Brechtel K; Scheinert D; Rastan A; Noory E; Beschorner U J Endovasc Ther; 2014 Dec; 21(6):765-74. PubMed ID: 25453876 [TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. McQuade K; Gable D; Hohman S; Pearl G; Theune B J Vasc Surg; 2009 Jan; 49(1):109-15, 116.e1-9; discussion 116. PubMed ID: 19028055 [TBL] [Abstract][Full Text] [Related]
20. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. Bosiers M; Deloose K; Callaert J; Moreels N; Keirse K; Verbist J; Peeters P J Vasc Surg; 2011 Oct; 54(4):1042-50. PubMed ID: 21636239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]